Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Tg Therapeutics (TGTX) over the last 15 years, with Dec 2024 value amounting to $22.8 million.

  • Tg Therapeutics' Change in Accured Expenses fell 248.08% to -$17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.9 million, marking a year-over-year decrease of 75.94%. This contributed to the annual value of $22.8 million for FY2024, which is 753.76% up from last year.
  • Per Tg Therapeutics' latest filing, its Change in Accured Expenses stood at $22.8 million for FY2024, which was up 753.76% from $2.7 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Change in Accured Expenses ranged from a high of $22.8 million in FY2024 and a low of -$31.5 million during FY2020.
  • Over the past 3 years, Tg Therapeutics' median Change in Accured Expenses value was $2.7 million (recorded in 2023), while the average stood at $4.8 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 203.97% in 2020, then surged by 753.76% in 2024.
  • Yearly analysis of 5 years shows Tg Therapeutics' Change in Accured Expenses stood at -$31.5 million in 2020, then soared by 48.75% to -$16.1 million in 2021, then spiked by 31.81% to -$11.0 million in 2022, then soared by 124.30% to $2.7 million in 2023, then skyrocketed by 753.76% to $22.8 million in 2024.